Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing a development strategy that integrates biomedical literature analysis with therapeutic development. At Drug Discovery 2026, held in Burlingame, California, company representatives Scott Myers and Saran Saund presented the company's PDAOAI platform, which is designed to help researchers organize scientific evidence and generate hypotheses for further investigation.
Myers, Oncotelic's Product Manager, delivered a presentation titled "The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development" on October 7. He described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. This capability addresses the challenge of navigating an ever-expanding body of scientific literature, enabling researchers to extract relevant insights more efficiently.
On October 8, Saund, Chief Business Officer, presented an HCC case study that demonstrated how disease-specific literature analysis led to the identification of a four-gene mTOR-related signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort. This finding could have implications for the development of targeted therapies and prognostic tools for hepatocellular carcinoma, a leading cause of cancer-related mortality worldwide.
The presentations underscore Oncotelic's commitment to leveraging artificial intelligence to accelerate drug discovery. By connecting biomedical literature analysis with practical therapeutic development, the company aims to streamline the identification of promising research avenues. Additionally, BIO REBOOT, an initiative mentioned in the release, connects the platform's research capabilities with potential funding and development support for selected projects, potentially fostering collaborations and accelerating the translation of research into clinical applications.
For investors and industry observers, Oncotelic's progress with PDAOAI and its HCC research may signal a broader trend toward integrating AI-driven tools in biotechnology. Such platforms could enhance research efficiency and reduce the time and cost associated with drug development. The latest news and updates relating to OTLC are available in the company's newsroom at ibn.fm/OTLC.
The announcement was distributed via InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. These services aim to help companies reach a wide audience of investors, journalists, and the public. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
